Expert panelists discuss the essential role of primary care in early skin cancer detection, balancing clinical judgment with emerging AI artificial intelligence tools, and more.

New data reveals lecanemab's significant impact on amyloid-beta protofibrils in Alzheimer disease, showcasing its potential to slow disease progression.

Panelists discuss how NK1 receptor antagonists show promise beyond VMS, suggesting wider therapeutic potential across neurological and systemic conditions.

Two-year structured lifestyle "recipe" slowed cognitive aging and enhanced both cardiovascular and sleep health in older adults at risk for cognitive decline.

Panelists discuss how NK receptor antagonists deliver fast symptom relief with strong safety profiles, improving adherence and clinical confidence in their use.

Your daily dose of the clinical news you may have missed.

Nearly one-third of caregivers hesitate to discuss agitation in a patient with AD. Emory's Clevenger, shares why and how clinicians can proactively address this barrier.

Lisa Larkin, MD, explains how new therapies like elinzanetant reflect a major shift in menopause care and rising demand for better clinician education.

The Priority Review decision is based on phase 3 results showing consistent SBP reductions across uncontrolled and treatment-resistant hypertension subgroups.

Biomarker trajectories over 5 years in study participants with AD show steeper rises in pTau217, NfL, and amyloid burden among those with obesity, highlighting risk factor relevance.

New findings reveal etalanetug significantly reduces tau biomarkers in Alzheimer’s patients, paving the way for innovative blood-based assessments of tau pathology.